Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11165374 | PMC |
| http://dx.doi.org/10.1001/jamanetworkopen.2024.15917 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of Glucagon-like Peptide-1 Receptor Agonist Use with Complications Following Thoracic and/or Lumbar Spinal Fusion for Degenerative Spine Disease: A BMI-Stratified Retrospective Study.
Spine (Phila Pa 1976)
September 2025
Department of Orthopaedic Surgery, Warren Alpert Medical School of Brown University, Providence, RI.
Article Synopsis
- The study investigates the impact of preoperative GLP-1 receptor agonist use on surgical outcomes for spinal fusion in patients with degenerative spine disease, focusing on different BMI categories.
- Significant findings show that GLP-1 RA users experienced lower rates of 90-day medical complications and reduced 2- and 10-year surgical revisions related to infection and mechanical failure, particularly in patients with higher BMI.
- The research utilized a national claims database and matched GLP-1 users to controls based on age, sex, and comorbidities to ensure reliable comparisons.
Assessing the Prognostic Accuracy of the PSS, pSOFA, and SIRS for In-Hospital Mortality in Children with Suspected Infection in Non-ICU Settings: A Multicenter Retrospective Study.
Int J Infect Dis
September 2025
Department of Clinical Laboratory, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health National Children's Regional Medical Center, Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, 311121, China. Electronic address: qingye
Objectives: To systematically compare the predictive accuracy of the Phoenix Sepsis Score (PSS), the Pediatric Sequential Organ Failure Assessment (pSOFA), and systemic inflammatory response syndrome (SIRS) in assessing in-hospital mortality risk among pediatric sepsis patients in non-ICU wards, thereby providing evidence-based support for clinical risk stratification.
Design: This study employed a multicenter retrospective cohort design, enrolling non-ICU pediatric patients with suspected infections (excluding preterm infants and neonates hospitalized immediately after birth), to construct an overall cohort and a neonatal subgroup cohort. Clinical parameters were collected through a data acquisition system, with parallel calculations of PSS, pSOFA, and SIRS scores.
Early enteral nutrition in critically-ill patients.
World J Crit Care Med
September 2025
Department of Gastroenterology and Hepatology, Creighton University School of Medicine, Phoenix, AZ 85012, United States.
Critically ill patients have a variety of complex pathologies and are in a multifarious state of catabolism supplanted by external and internal factors. Early enteral nutrition (EEN) is defined as the initiation of enteral feeding within 24-48 hours of hospitalization. Previous studies show the benefits of EEN include supporting the healing process through preservation of the gut mucosa, modulation of the immune response, and suppression of inflammation.
View Article and Find Full Text PDFPrevalence of Hidradenitis Suppurativa: A Meta-Analysis of Global Hidradenitis Suppurativa Atlas Studies.
JAMA Dermatol
August 2025
Department of Dermatology, Deventer Hospital, Deventer, the Netherlands.
Importance: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a substantial burden. Standardized global prevalence estimates and data on associated sociodemographic and risk factors are lacking.
Objective: To estimate the global prevalence of HS and study differences in prevalence by age, sex, geographical location, body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), smoking status, gross domestic product (GDP), and Human Development Index (HDI).
Pharmacokinetics of Sulbactam/Durlobactam in a Patient With Acute Renal Failure, Severe Obesity, and Carbapenem-Resistant Acinetobacter baumannii Bacteremia: A Case Report.
Pharmacotherapy
August 2025
Center for Anti-Infective Research & Development, Hartford Hospital, Hartford, Connecticut, USA.
Carbapenem-resistant Acinetobacter baumannii (CRAB) are difficult-to-treat pathogens that primarily cause health care-associated infections. Sulbactam/durlobactam (SUL/DUR) is a novel antibiotic combination that is uniquely formulated to target CRAB isolates. However, investigations of SUL/DUR's pharmacokinetics in obese patients are limited.
View Article and Find Full Text PDF